Form 4: Cibus CSO Sells Shares for Tax Obligations

Cibus Inc.'s Chief Scientific Officer, Gregory Gocal, disposed of 8,954 Class A Common Stock shares at a weighted average price of $1.82 to cover tax liabilities.

Summary

• Gregory Francis William Gocal, Chief Scientific Officer & EVP of Cibus, Inc. (CBUS), reported a disposition of shares.
• On March 30, 2026, Gocal disposed of 8,954 shares of Class A Common Stock.
• The shares were sold at a weighted average price of $1.82 per share, with individual transactions ranging from $1.795 to $1.86.
• Following this transaction, Gocal beneficially owns 365,890 shares of Class A Common Stock.
• The transaction code 'F' indicates a sale to cover tax withholding obligations upon the vesting of restricted stock or similar equity awards.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine disposition of shares to cover tax liabilities associated with equity compensation, rather than a discretionary sale based on market sentiment.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as sales to cover tax obligations upon equity vesting, are common across all industries and typically do not reflect a change in management's outlook on the company's prospects. These transactions are often pre-scheduled under Rule 10b5-1 plans.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in confidence.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations. This type of transaction is common and does not typically signal a change in the company's fundamentals or the executive's long-term view. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Cibus Inc., CBUS, Form 4, Insider Trading, Stock Sale, Executive Compensation, Gregory Gocal, Chief Scientific Officer, Equity Disposition